Ben Auspitz is a Partner at F-Prime Capital, and has worked in pharmaceuticals and life-science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into phase II clinical studies, and was co-inventor on 15 product patents.
Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, Indalo Therapeutics, Akrevia Therapeutics, Modis Therapeutics, and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics. Companies he has funded have brought four drugs through regulatory approval.
He currently serves on the Board of Directors of Indalo Therapeutics, Akrevia Therapeutics, Turnstone Biologics, Checkmate Pharmaceuticals, and Compass Therapeutics and serves as Chairman of Modis Therapeutics. Previously, Ben was involved in F-Prime Capital investments in Symbiomix Therapeutics (acquired by Lupin), Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Dimension Therapeutics (Acquired by Ultragenyx), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Unum Therapeutics (NASDAQ:UMRX), Orchard Therapeutics (NASDAQ: ORTX), and Ultragenyx (NASDAQ: RARE).
He holds a B.A. from Harvard University.